πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Renovaro Biosciences Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Rencofilstat

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drug therapies for chronic liver diseases, particularly through the development of Rencofilstat, a cyclophilin inhibitor aimed at treating non-alcoholic steatohepatitis (NASH) and reducing liver fibrosis and tumors.

Tags: NASH, Rencofilstat, biopharmaceutical, cyclophilin inhibitor, drug therapy, liver disease

Symbol: HEPA

Recent Price: $0.43

Industry: Biotechnology

CEO: Mr. John Patrick Brancaccio CPA

Sector: Healthcare

Employees: 22

Address: 399 Thornall Street, Edison, NJ 08837

Phone: 732 902 4000

Leadership

  • John P. Brancaccio, Interim Chief Executive Officer, Interim Chief Financial Officer, and Chairman of the Board

Last updated: 2024-12-31

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

ENHANZE drug delivery technology

Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enabling subcutaneous delivery of biologics using its patented ENHANZE technology. The company operates in the United States and internationally, offering products such as Hylenex recombinant and developing treatments for various medical conditions including lymphomas and immunodeficiency disorders.

Tags: ENHANZE, biologics, biopharma, drug delivery, technology, therapeutics

Symbol: HALO

Recent Price: $47.99

Industry: Biotechnology

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Sector: Healthcare

Employees: 373

Address: 11388 Sorrento Valley Road, San Diego, CA 92121

Phone: 858 794 8889

Last updated: 2024-12-31

Revelation Biosciences, Inc.

Revelation Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

REVTx-99b

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing immune system therapeutics and diagnostics, including products for chronic nasal congestion, allergic rhinitis, chronic organ disease, and viral infections.

Tags: allergic rhinitis, biopharmaceutical, clinical trial, diagnostics, immune system therapeutics, kidney disease, nasal congestion, viral infections

Symbol: REVB

Recent Price: $0.39

Industry: Biotechnology

CEO: Mr. James M. Rolke

Sector: Healthcare

Employees: 9

Address: 4660 La Jolla Village Drive, San Diego, CA 92122

Phone: 650-800-3717

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Arvinas, Inc.

Arvinas, Inc. logo
Market Cap: High
Employees: Medium

Bavdegalutamide, ARV-471, ARV-766

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is based in New Haven, Connecticut and collaborates with organizations like Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.

Tags: PROTAC, biopharmaceutical, cancer therapy, clinical-stage, protein degrader

Symbol: ARVN

Recent Price: $19.00

Industry: Biotechnology

CEO: Dr. John G. Houston Ph.D.

Sector: Healthcare

Employees: 445

Address: 5 Science Park, New Haven, CT 06511

Phone: 203 535 1456

Leadership

  • John G. Houston, Ph.D., Chairperson, Chief Executive Officer, and President
  • Noah Berkowitz, M.D., Ph.D., Chief Medical Officer
  • Angela M. Cacace, Ph.D., Chief Scientific Officer
  • Jared Freedberg, J.D., General Counsel and Corporate Secretary
  • Paul McInulty, Senior Vice President, Regulatory Affairs
  • John Northcott, Chief Commercial Officer
  • Kelly Page, Senior Vice President, Global Head of Oncology Strategy and Program Leadership
  • Andrew Saik, Chief Financial Officer
  • Lisa Sinclair, Senior Vice President, Corporate Operations
  • Ian Taylor, Ph.D., President, R&D
  • Randy Teel, Ph.D., Chief Business Officer
  • Steve Weiss, Senior Vice President, Chief Human Resources Officer

Last updated: 2024-12-31

Assembly Biosciences, Inc.

Assembly Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Vebicorvir

Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Their lead product candidate, Vebicorvir, has completed Phase 2 clinical trials. The company is engaged in additional development and collaboration agreements to advance treatments for HBV.

Tags: Vebicorvir, biotechnology, clinical trials, hepatitis B, therapeutics

Symbol: ASMB

Recent Price: $16.03

Industry: Biotechnology

CEO: Mr. Jason A. Okazaki

Sector: Healthcare

Employees: 65

Address: 331 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 833 509 4583

Last updated: 2024-12-31

Benitec Biopharma Inc.

Benitec Biopharma Inc. logo
Market Cap: Low
Employees: Lowest

BB-301 and BB-103

Benitec Biopharma Inc. is a development-stage biotechnology company specializing in DNA-directed RNA interference-based therapeutics for chronic and life-threatening conditions. Its lead products include BB-301 for oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.

Tags: RNA interference, biotechnology, chronic conditions, gene therapy, genetic medicines, hepatitis B, oculopharyngeal muscular dystrophy

Symbol: BNTC

Recent Price: $12.51

Industry: Biotechnology

CEO: Dr. Jerel A. Banks M.D., Ph.D.

Sector: Healthcare

Employees: 16

Address: 3940 Trust Way, Hayward, CA 94545

Phone: 510 780 0819

Leadership

  • Jerel Banks, M.D., Ph.D., Chief Executive Officer & Chairman of the Board
  • Megan Boston, Executive Director

Last updated: 2024-12-31

Coherus BioSciences, Inc.

Coherus BioSciences, Inc. logo
Market Cap: Low
Employees: Low

UDENYCA

Coherus Bio Sciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. It markets UDENYCA and develops various biosimilar and immuno-oncology products.

Tags: Toripalimab, UDENYCA, biopharmaceutical, biosimilars, immuno-oncology

Symbol: CHRS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Dennis M. Lanfear

Sector: Healthcare

Employees: 306

Address: 333 Twin Dolphin Drive, Redwood City, CA 94065

Phone: 650 649 3530

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Heron Therapeutics, Inc.

Heron Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

SUSTOL, CINVANTI, ZYNRELEF

Heron Therapeutics, Inc. is a biotechnology company focused on developing treatments to address unmet patient needs, utilizing its proprietary Biochronomer drug delivery technology.

Tags: biotechnology, cancer treatment, chemotherapy, drug delivery, nausea prevention

Symbol: HRTX

Recent Price: $1.51

Industry: Biotechnology

CEO: Mr. Craig Alexander Collard

Sector: Healthcare

Employees: 126

Address: 4242 Campus Point Court, San Diego, CA 92121

Phone: 858 251 4400

Leadership

  • Adam Morgan, Chairman
  • Sharmila Dissanaike, M.D., FACS, FCCM, Director
  • Craig Johnson, Lead Independent Director
  • Susan Rodriguez, Director
  • Christian Waage, Director
  • Craig Collard, Director
  • Brett Fleshman, Chief Business Officer

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Renovaro Biosciences Inc.

Renovaro Biosciences Inc. logo
Market Cap: Lowest
Employees: Lowest

RENB-HV-01, RENB-HV-12, RENB-HB-01, RENB-DC-11, RENB-DC-12-XX, RENB-HV-21

Renovaro Biosciences Inc. is a pre-clinical stage biotechnology company focused on R&D of pharmaceutical and biological products for treating HIV, HBV, and cancer in the U.S. The company has a robust product pipeline and strategic partnerships, and was formerly known as Enochian Biosciences, Inc.

Tags: HBV treatment, HIV treatment, biotechnology, cancer treatment, pharmaceutical research, strategic partnerships

Symbol: RENB

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. David H. Weinstein

Sector: Healthcare

Employees: 25

Address: 2080 Century Park East, Los Angeles, CA 90067

Phone: 305 918 1980

Last updated: 2024-12-31

RenovoRx, Inc.

RenovoRx, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renovo Gem

Renovo Rx, Inc. is a clinical-stage biopharmaceutical company focusing on developing therapies for the treatment of solid tumors, with its lead product candidate, Renovo Gem, in Phase III clinical trials for locally advanced pancreatic cancer.

Tags: Renovo Gem, biopharmaceutical, clinical trials, pancreatic cancer, solid tumors

Symbol: RNXT

Recent Price: $1.39

Industry: Biotechnology

CEO: Mr. Shaun R. Bagai

Sector: Healthcare

Employees: 8

Address: 4546 El Camino Real, Los Altos, CA 94022

Phone: 650 284 4433

Leadership

  • Shaun R. Bagai, Director and Chief Executive Officer
  • Ramtin Agah, MD, Chairman, Chief Medical Officer, and Founder
  • Leesa Gentry, Chief Clinical Officer
  • Ronald B. Kocak, CPA, VP Controller and Principal Accounting Officer
  • Ryan Witt, Senior Vice President, Head of Corporate Strategy and Partnerships
  • Imtiaz Qureshi, MD, Director of Imaging
  • Angela Macfarlane, CEO of Perceive Biotherapeutics, Inc.
  • Laurence J. Marton, MD, Director
  • Una S. Ryan, PhD, OBE, Director
  • Robert J. Spiegel, Director

Last updated: 2024-12-31

Sana Biotechnology, Inc.

Sana Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

N/A

Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines, developing cell engineering platforms for various therapeutic areas including oncology, diabetes, and genetic disorders.

Tags: biotechnology, cell engineering, genetic disorders, medicine, oncology

Symbol: SANA

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Steven D. Harr M.D.

Sector: Healthcare

Employees: 328

Address: 188 East Blaine Street, Seattle, WA 98102

Phone: 206 701 7914

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Vor Biopharma Inc.

Vor Biopharma Inc. logo
Market Cap: Lowest
Employees: Low

VOR33

Vor Biopharma, Inc. is a clinical-stage company focused on developing engineered hematopoietic stem cell (e HSC) therapies for cancer patients, with a leading product, VOR33, in phase 1/2 trials for AML and other hematological malignancies.

Tags: AML, biotechnology, cancer therapies, e HSC, hematopoietic stem cells

Symbol: VOR

Recent Price: $1.19

Industry: Biotechnology

CEO: Dr. Robert Ang M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 168

Address: 100 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 655 6580

Leadership

  • Robert Ang, MBBS, MBA, President and Chief Executive Officer
  • Eyal Attar, MD, Chief Medical Officer
  • Tirtha Chakraborty, PhD, Chief Scientific Officer
  • Han Choi, MD, LLM, Chief Financial Officer
  • John King, MBA, Chief Commercial Officer and Head of Business Development
  • Tania Philipp, Chief People Officer
  • David Phillips, MBA, Senior Vice President, Head of Quality
  • Samir Vattompadam, MS, Senior Vice President, Portfolio Strategy and Program Management
  • Daniella Beckman, Board of Directors
  • David Lubner, Board of Directors
  • Bill Lundberg, MD, Board of Directors
  • Fouad Namouni, MD, Board Of Directors
  • Matthew R. Patterson, Chairman, Board of Directors
  • Josh Resnick, MD, Board of Directors

Last updated: 2024-12-31

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renazorb, UNI 494

Unicycive Therapeutics is a biotech company developing novel therapies for kidney diseases in the United States, focusing on treatments for hyperphosphatemia and acute kidney injury.

Tags: Renazorb, UNI 494, acute kidney injury, biotechnology, hyperphosphatemia, kidney diseases

Symbol: UNCY

Recent Price: $0.58

Industry: Biotechnology

CEO: Dr. Shalabh K. Gupta M.D., MPA

Sector: Healthcare

Employees: 14

Address: 4300 El Camino Real, Los Altos, CA 94022

Phone: 650 351 4495

Last updated: 2024-11-08

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation logo
Market Cap: Medium
Employees: Low

AB-729, AB-836, AB-161, AB-101

Arbutus Biopharma Corporation is a biopharmaceutical company that develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. The company's HBV product pipeline includes RNA interference products and oral capsid inhibitors, and it is involved in strategic alliances for research and development.

Tags: HBV, Hepatitis B, RNA interference, SARS-CoV-2, biopharmaceutical, capsid inhibitor, coronaviruses, therapeutics

Symbol: ABUS

Recent Price: $3.20

Industry: Biotechnology

CEO: Mr. Michael J. McElhaugh

Sector: Healthcare

Employees: 73

Address: 701 Veterans Circle, Warminster, PA 18974

Phone: 267 469 0914

Leadership

  • Michael J. McElhaugh, Interim President and Chief Executive Officer and Director
  • Michael J. Sofia PhD, Chief Scientific Officer
  • Karen Sims, MD, PhD, Chief Medical Officer
  • David C. Hastings, Chief Financial Officer
  • Christopher Naftzger, General Counsel and Chief Compliance Officer
  • Lisa Caperelli, Vice President, Investor Relations
  • Shannon Briscoe, SPHR, SHRM-SCP, Vice President, Human Resources
  • Frank Torti, MD, Chairman
  • Daniel Burgess, Independent Director
  • Richard C. Henriques, Independent Director
  • Keith Manchester, MD, Independent Director
  • James Meyers, Independent Director
  • Melissa V. Rewolinski, PhD, Independent Director

Last updated: 2024-12-31

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

N/A

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.

Tags: SARS-Co V-2, biotechnology, hepatitis B virus, liver diseases, pharmaceuticals, respiratory syncytial virus, small molecule drugs, viral infections

Symbol: ENTA

Recent Price: $5.85

Industry: Biotechnology

CEO: Dr. Jay R. Luly Ph.D.

Sector: Healthcare

Employees: 145

Address: 500 Arsenal Street, Watertown, MA 02472

Phone: 617 607 0800

Leadership

  • Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
  • Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
  • Matthew P. Kowalsky, J.D., Chief Legal Officer
  • Brendan Luu, Chief Business Officer
  • Paul J. Mellett, Chief Financial and Administrative Officer
  • Yat Sun Or, Ph.D., Chief Scientific Officer
  • Scott T. Rottinghaus, M.D., Chief Medical Officer
  • Bruce L.A. Carter, Ph.D., Chairman of the Board
  • Mark G. Foletta, Board Member
  • Yujiro S. Hata, Board Member
  • Kristine Peterson, Board Member
  • Lesley Russell, MBChB, MRCPb, Board Member
  • Terry Vance, Board Member

Last updated: 2024-12-31

IN8bio, Inc.

IN8bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

INB-200, INB-100, INB-400, INB-300

IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.

Tags: biopharmaceutical, biotechnology, cancer treatment, clinical trials, gamma-delta T cell therapies

Symbol: INAB

Recent Price: $0.27

Industry: Biotechnology

CEO: Mr. Tai-Wei Ho

Sector: Healthcare

Employees: 39

Address: 350 5th Avenue, New York, NY 10118

Phone: 646 600 6438

Last updated: 2024-12-31